Conference - The future of ARVs in Africa
![](/FileUpload/SAHCS LAI Conference 2024 Banner 1000.jpg)
We are delighted to invite you to join us for the 2nd Southern African HIV Clinicians Society (SAHCS) long-acting treatment and prevention conference entitled ‘The future of antiretrovirals in Africa: Long-acting agents and beyond’.
Chaired by Professor Catherine Orrell and Dr Nosisa Sipambo, the conference is set to take place on Tuesday, 29 October 2024 at the Maslow Hotel, corner of Rivonia Road and Grayston Drive, Sandton, Johannesburg.
The conference will focus on long-acting treatment and prevention, with program sessions including outcomes of implementation studies, prevention studies, and treatment studies, amongst other related topics.
Prevention of HIV infection is the cornerstone of controlling the global HIV pandemic. The conference will provide healthcare professionals with up-to-date clinical knowledge and clinical skills development around patient treatment, care and support.
PROVISIONAL PROGRAMME
REGISTRATION INFORMATION
Registration is now open!
Registration Fee R800.00 (including VAT) per person
CLICK HERE to register
To make payment for your conference registration please following this Payfast link:
If you have any questions, please do not hesitate to contact the secretariat, Janice Candlish, at [email protected] or telephone +27(0)11 728 7365.
Previous conference information:
The 1st SAHCS long-acting treatment and prevention conference, hosted on 20 September 2022 at Indaba Hotel in Fourways, was filled with brilliant presentations from top HIV-experts with a highly engaged audience and powerful discussions - there may be barriers but if we all come together and deliver scientific solutions through a person-centered approach alongside statutory support we can curb this HIV epidemic!
20 September 2022 - Conference programme – download here
Conference presentations:
- Islatravir (MK-8591) - NRTTI | Dr Bronywyn Bosch
- Long-Acting Injectables and resistance in the South African context | Dr Bronywyn Bosch
- Long-acting agents and beyond for the children and adolescents with HIV | Prof Mo Archary
- Guideline considerations for LAIs: How should Africa be thinking about this? | Prof Francois Venter
- Cabotegravir as PrEP: Lessons from HPTN 083 and HPTN 084 | Dr Carrie-Anne Mathew